Feburic Label to Be Revised due to CV Risk, but No Patient Restrictions to Be Required “at Present”

Meeting of the subcommittee on Safety of Drugs on June 26 The Ministry of Health, Labor and Welfare (MHLW) on June 26 presented a number of measures to be taken for the risk of cardiovascular death related to Teijin Pharma’s...read more